Currently, researchers based out of Halifax are in the pre-clinical trial stage, and are waiting for ethics board approval to move on.
From there, Phase 1 testing will begin, and that could happen within the next week or two, according to Dr. Alyson Kelvin, who is with Dalhousie University and a researcher with the Canadian Centre for Vaccinology.
Phase 1 consists of testing less than 100 healthy people between the ages of 18 and 55, to see if the vaccine is safe.
Kelvin tells News 95.7, the Phase 1 testing does not indicate whether the vaccine works against the virus or not.
“We can see hints of, is this vaccine able to produce an immune response that would recognize the virus if the vaccinated person had become encountered with this virus,” she says.
Phase 2 testing would involve closer to 500 people, and they would hail from an older age demographic, to see how safe it is for the older population.
From there, Phase 3 testing would be the stage where the effectiveness against the virus would be determined, which could take place by the fall.
And in a best case scenario, if Phase 3 testing is a success, a vaccine approved for population use could happen by December 2020, into the new year of 2021.
The team will continue work started by their partners at the Chinese manufacturer CanSino Biologics, which has already begun human vaccine trials in China.